| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
Desmosterol is a key activator of liver X receptors (LXR) while inhibiting sterol regulatory element-binding protein (SREBP) to regulate lipid homeostasis. It can suppress macrophage inflammasome activation and prevent vascular inflammation and atherosclerosis. Its reduction promotes mitochondrial ROS production in macrophages and activates the NLRP3 inflammasome.
|
|---|---|
| ln Vitro |
In vitro, desmosterol acts as an LXR activator and SREBP inhibitor. It suppresses macrophage inflammasome activation. It is used in research to study sterol metabolism and the regulation of cholesterol synthesis.
|
| ln Vivo |
In vivo, desmosterol prevents vascular inflammation and atherosclerosis. It plays a vital role in the production of sterols and is involved in various cellular processes, including membrane structure, lipid metabolism, and the regulation of cell signaling.
|
| Enzyme Assay |
In vitro receptor binding assays for desmosterol typically measure its ability to activate LXR. Radiolabeled LXR ligands are displaced by increasing concentrations of the compound to determine binding affinity. Functional assays measure the compound's ability to activate LXR-mediated transcription using reporter gene assays.
|
| Cell Assay |
Cell-based assays for desmosterol involve treating macrophages with the compound and measuring its effects on inflammasome activation, cytokine production, and lipid metabolism. The compound's ability to suppress inflammation and modulate cholesterol metabolism is assessed.
|
| Animal Protocol |
In vivo animal studies for desmosterol are conducted in models of atherosclerosis and inflammation. The compound is administered, and its effects on atherosclerotic lesion size, vascular inflammation, and lipid levels are assessed.
|
| ADME/Pharmacokinetics |
Desmosterol has a molecular weight of 384.64 and a molecular formula of C27H44O. It is soluble in organic solvents. For storage, it should be kept at -20°C.
|
| Toxicity/Toxicokinetics |
The toxicological profile of desmosterol has not been extensively characterized. As an endogenous metabolite, it is generally considered to have low toxicity. However, as with any research compound, appropriate safety precautions should be taken when handling it.
|
| References |
Wudiri GA, Nicola AV. Cellular cholesterol facilitates the post-entry replication cycle of herpes simplex virus 1. J Virol. 2017 Apr 26. pii: JVI.00445-17. doi: 10.1128/JVI.00445-17. [Epub ahead of print] PubMed PMID: 28446672.
|
| Additional Infomation |
Desmosterol is a cholesterol compound with the structure cholester-5,24-diene, substituted with a β-hydroxyl group at the 3-position. It is an intermediate metabolite in cholesterol synthesis and has been found in both humans and mice. It is a 3β-sterol, cholesterol compound, C27-steroid, and 3β-hydroxy-Δ5-steroid. Desmosterol has been reported to exist in Mortierella alpina, Gossypium hirsutum, and other organisms with relevant data. It is an intermediate in cholesterol synthesis.
Desmosterol is the immediate precursor of cholesterol in the Bloch pathway. It is an LXR activator and SREBP inhibitor. It suppresses macrophage inflammasome activation and prevents vascular inflammation and atherosclerosis. It is a valuable research tool for studying cholesterol metabolism, inflammation, and atherosclerosis. |
| Molecular Weight |
384.63766
|
|---|---|
| Exact Mass |
384.339
|
| CAS # |
313-04-2
|
| Related CAS # |
313-04-2;
|
| PubChem CID |
439577
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
483.2±14.0 °C at 760 mmHg
|
| Melting Point |
121.5ºC
|
| Flash Point |
209.2±12.4 °C
|
| Vapour Pressure |
0.0±2.8 mmHg at 25°C
|
| Index of Refraction |
1.536
|
| LogP |
9.54
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
28
|
| Complexity |
641
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C[C@H](CCC=C(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C
|
| InChi Key |
AVSXSVCZWQODGV-DPAQBDIFSA-N
|
| InChi Code |
InChI=1S/C27H44O/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28)13-15-26(20,4)25(22)14-16-27(23,24)5/h7,9,19,21-25,28H,6,8,10-17H2,1-5H3/t19-,21+,22+,23-,24+,25+,26+,27-/m1/s1
|
| Chemical Name |
(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylhept-5-en-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5998 mL | 12.9992 mL | 25.9983 mL | |
| 5 mM | 0.5200 mL | 2.5998 mL | 5.1997 mL | |
| 10 mM | 0.2600 mL | 1.2999 mL | 2.5998 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA